[go: up one dir, main page]

WO2018145664A1 - 提高耐力表现的抗疲劳组合物 - Google Patents

提高耐力表现的抗疲劳组合物 Download PDF

Info

Publication number
WO2018145664A1
WO2018145664A1 PCT/CN2018/076630 CN2018076630W WO2018145664A1 WO 2018145664 A1 WO2018145664 A1 WO 2018145664A1 CN 2018076630 W CN2018076630 W CN 2018076630W WO 2018145664 A1 WO2018145664 A1 WO 2018145664A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
component
group
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/076630
Other languages
English (en)
French (fr)
Inventor
黄文芳
吴雅婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinphar Tian Li Pharmaceutical Co Ltd
Original Assignee
Sinphar Tian Li Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinphar Tian Li Pharmaceutical Co Ltd filed Critical Sinphar Tian Li Pharmaceutical Co Ltd
Priority to MYPI2019004642A priority Critical patent/MY192107A/en
Publication of WO2018145664A1 publication Critical patent/WO2018145664A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A23V2250/314—Ubiquinone, coenzyme Qn

Definitions

  • the present invention relates to a composition
  • a composition comprising a Cistanche tubulosa extract as a first component and an oxidized coenzyme (Q10) and/or a reduced coenzyme (QH) as a second component.
  • the invention also relates to the use of the composition in anti-fatigue, in particular to the use of the composition in at least one of the following: treating chronic fatigue syndrome, preventing chronic fatigue syndrome, improving endurance performance, improving athletic ability, enhancing physical strength, restoring physical strength, Promotes fatigue elimination, prevents myocardial weakness, helps the heart to improve, and helps improve heart function.
  • Fatigue refers to the operation of the body's physiological function that cannot be maintained at a certain level and/or the ability of the organ (such as the heart) to maintain its original working ability, resulting in decreased exercise capacity and physical strength. However, if you are under excessive stress or excessive labor for a long time, your body will not be able to fully enjoy rest, and you will not be able to eliminate fatigue or burnout. Fatigue or burnout is a warning from the body that, in general, can be eliminated by resting the body. However, if you are over-stressed or over-worked for a long time, your body will not be able to get enough rest.
  • CFS Chronic Fatigue Syndrome
  • the Chinese herbal medicine Herba Cistanches was first recorded in the Shennong Bencao Classic. It is one of the perennial parasitic herbaceous plants of the Orobanchaceae family. It relies on the nutrient life of the host plant Salvia, and is distributed in deserts and deserts. The dry zone is a valuable and rare Cistanche herb.
  • Oxidized coenzyme (Q10) is mainly found in the mitochondria of eukaryotic cells. It acts as a coenzyme of the electron transport chain and participates in the aerobic respiration of cells, which promotes the energy required for ATP production to supply cells.
  • the reduced coenzyme (QH) is a reduced form of oxidized coenzyme (Q10), which can be directly absorbed and utilized by the human body without conversion in vivo, so its bioavailability is higher than that of oxidized coenzyme (Q10).
  • the composition can Apply to at least one of the following: treatment of chronic fatigue syndrome, prevention of chronic fatigue syndrome, improvement of endurance performance, improvement of exercise capacity, enhancement of physical strength, recovery of physical strength, promotion of fatigue elimination, prevention of myocardial weakness, help of heart weakness, and improvement of cardiac function .
  • the present invention can provide an anti-fatigue composition having excellent effects at a relatively low manufacturing cost by the combination of the first component and the second component described above, and is economically advantageous.
  • Cistanche tubulosa extract is a polar solvent extract of Cistanche tubulosa, wherein the polar solvent is selected from the group consisting of water, C1-C4 alcohols, and combinations of the foregoing.
  • the composition provided according to the present invention further comprises at least one of the following: vitamin B group, Rhodiola rosea extract, Schisandra chinensis extract, vitamin E, ribose, hawthorn extract , magnesium, calcium, fish oil, taurine, chicken essence, acanthopanax extract, ginseng extract, quercetin, cordyceps extract, soy protein isolate, BCAA (branched amino acid), carnitine, isomaltulose , glucose, probiotics, whey protein, milk protein isolate, GABA (gamma-aminobutyric acid), gastrodia elata extract, L-tryptophan, and ⁇ -oryzanol. More preferably, the composition further comprises one selected from the group consisting of vitamin B1, a derivative of vitamin B1, a vitamin B6, a derivative of vitamin B6, and combinations of the foregoing.
  • the composition provided according to the present invention is an anti-fatigue pharmaceutical composition, food composition, cosmetic composition, skin care composition, or feed composition.
  • the pharmaceutical composition is for treating or preventing chronic fatigue syndrome.
  • the pharmaceutical composition is in the form of oral, transdermal, intravenous, or subcutaneous injection.
  • the anti-fatigue food composition, cosmetic composition, skin care composition, or feed composition provided according to the present invention is used for at least one of improving endurance performance, improving exercise capacity, enhancing physical strength, and restoring physical strength. Promote fatigue elimination, prevent myocardial weakness, help the heart to improve, and help improve heart function.
  • the food composition may be a health food, a health food, a functional food, a nutritional supplement or a special nutritious food.
  • the food composition is a dairy product, a meat processed product, a bread, a noodle food, a biscuit, Ingots, capsules, juices, teas, sports drinks, nutritious drinks, soups, powders, jellies, soft candy, solid-liquid mixed soups, or solid-liquid mixed drinks.
  • Another object of the present invention is to provide a method of combating fatigue comprising administering an effective amount of the above composition to an individual in need thereof.
  • the method of the invention can be used for at least one of the following: treating chronic fatigue syndrome, preventing chronic fatigue syndrome, improving endurance performance, improving exercise capacity, enhancing physical strength, restoring physical strength, promoting fatigue elimination, preventing myocardial weakness, helping heart inability to improve, and helping Cardiac function improvement.
  • Figure 1A and Figure 1B show the results of mitochondrial ATP production and oxygen consumption, and the maximum respiratory oxygen consumption rate, including the "control group”, "TNF- ⁇ group” and “experiment group groups 1 to 15".
  • the "control group” is cultured in a medium containing no TNF- ⁇ , Cistanche tubulosa extract and reduced coenzyme
  • the "TNF- ⁇ group” contains TNF- ⁇ , but does not contain Cistanche tubulosa extract
  • the medium is cultured in a medium containing reduced coenzyme
  • the "experiment group groups 1 to 15" are cultured in a medium containing TNF- ⁇ , Cistanche tubulosa extract and/or reduced coenzyme;
  • FIGS. 2A and 2B show the glycolysis level and glycolysis reserve of muscle cells, respectively, including the results of the above-mentioned "control group”, "TNF- ⁇ group” and "experiment group groups 1 to 15";
  • Figure 3 shows the exhaustion time of the mouse weight-bearing swimming, including the results of the "vehicle group", “group I", “group II” and “group III", wherein the "vehicle group” feeding only contains a carrier composition (excluding Cistanche tubulosa extract and reduced coenzyme), Group I mice were fed a carrier containing a carrier and a weight ratio of 1.67:1 (Cistanche tubulosa extract: reduced coenzyme) The group II mice were fed a composition containing a carrier and a weight ratio of 3.33:1 (Cistanche tubulosa extract: reduced coenzyme), and the group III mice were fed with a carrier and the weight ratio was 6.67:1. a composition of Cistanche tubulosa extract: reduced coenzyme;
  • Figure 4 is a graph showing the forearm grip of a mouse after weight-bearing swimming, including the results of the above-mentioned "vehicle group", “group I”, “group II”, and “group III” mice;
  • FIG. 5A to 5E show blood biochemical values of the above-mentioned "vehicle group”, “group I”, “group II”, and “group III” mice after swimming, wherein FIG. 5A shows blood lactate. (serum lactate), Figure 5B shows serum ammonia, Figure 5C shows serum free fatty acid, Figure 5D shows serum glucose, and Figure 5E shows blood creatine kinase , CK) activity.
  • FIG. 5A shows blood lactate. (serum lactate)
  • Figure 5B shows serum ammonia
  • Figure 5C shows serum free fatty acid
  • Figure 5D shows serum glucose
  • Figure 5E shows blood creatine kinase , CK) activity.
  • the so-called “individual” refers to a human or a non-human mammal;
  • "Prevention” means inhibiting or preventing the onset of a specific condition, or maintaining a good state of health of a sensitive individual or establishing the individual's tolerance to the disease;
  • the so-called “treatment” should not be interpreted as treating a body until complete recovery, and It should include maintaining the disease progression or symptoms of a subject at a substantially static level, increasing the rate of recovery of a subject, reducing the severity of a particular condition, or improving the quality of life of a patient.
  • the "weight ratio" of the components contained in the composition is on a dry weight basis;
  • the so-called “dry weight” means that each component (for example, the first component, the second component) Weighing in the state of dry matter, and calculating the required amount;
  • the so-called “endurance performance” refers to the length of time during which the muscle can continue to operate in the presence of resistance.
  • compositions comprising a Cistanche tubulosa extract as a first component and an oxidized coenzyme (Q10) and/or a reduced coenzyme (QH) as a second component
  • the composition in which the weight ratio of the first component to the second component is from 0.67:1 to 10:1 can effectively slow down the decrease of the cell oxygen consumption rate induced by TNF- ⁇ and slow down the induction of TNF- ⁇ .
  • the extracellular acidity is abnormal, the endurance and muscle performance of the mouse are improved, the blood metabolites after the exercise of the mouse are lowered, and the stored energy in the blood of the mouse is provided, so that the anti-fatigue effect is obtained.
  • the above composition is generally considered to be useful for at least one of: treating chronic fatigue syndrome, preventing chronic fatigue syndrome, improving endurance performance, improving exercise capacity, enhancing physical strength, restoring physical strength, promoting fatigue elimination, preventing myocardial weakness, and helping the heart to improve, And help the heart function improve.
  • the present invention provides a composition
  • a composition comprising as an first component a Cistanche tubulosa extract and as a second component an oxidized coenzyme (Q10) and/or a reduced coenzyme (QH)
  • the weight ratio of the first component to the second component is from 0.67:1 to 10:1, preferably from 0.67:1 to 6.67:1, more preferably from 1.67:1 to 6.67:1.
  • the Cistanche tubulosa extract may be an extract or a dried product provided by drying the extract, wherein the extract is obtained by using a polar solvent to extract the tube flower Cistanche raw material, the extract provided.
  • the raw material of Cistanche tubulosa can be any part of Cistanche tubulosa, for example, the stem, flower or whole plant of Cistanche tubulosa can be used as an extraction raw material.
  • the fleshy stem of Cistanche tubulosa is used as an extraction material.
  • the polar solvent employed may be water, a C1-C4 alcohol, or a combination of the foregoing.
  • the polar solvent Preferably, water, ethanol, or a combination thereof is used as the polar solvent.
  • the ratio of the polar solvent used for the extraction to the cistanche raw material can be adjusted as needed.
  • the amount of the polar solvent is not particularly limited as long as the raw material can be uniformly dispersed.
  • the Cistanche tubulosa raw material may be repeatedly extracted in the same or different polar solvents, and the extract obtained by the multiple extraction may be combined and then dried.
  • the extraction time may be adjusted as needed to achieve the desired degree of extraction.
  • Taking water as the extraction solvent is usually, for example, at least 15 minutes, preferably at least 30 minutes, more preferably at least 60 minutes.
  • other operations such as boiling, cooling, filtration, concentration under reduced pressure, resin column chromatography, and the like may be supplemented to enhance the extraction efficiency.
  • the oxidized coenzyme (Q10) and/or reduced coenzyme (QH) as a second component contained in the composition of the present invention may be provided by any suitable source, for example, commercially available, and commercially available. Microbial fermentation is provided, or obtained by chemical synthesis. For example, oxidized coenzymes and reduced coenzymes are commercially available from Kaneka Corporation.
  • composition provided according to the present invention may further comprise one or more other active ingredients or may be used in combination with a drug or a food containing the one or more other active ingredients to further enhance the efficacy of the composition or to increase the formulation of the preparation.
  • the flexibility and the degree of blending are used as long as the other active ingredients do not adversely affect the benefits of the first component and the second component of the present invention.
  • the composition of the invention comprises one selected from the group consisting of vitamin B1, a derivative of vitamin B1, a vitamin B6, a derivative of vitamin B6, and combinations of the foregoing.
  • the composition provided according to the present invention may be a pharmaceutical composition, a food composition, a cosmetic composition, a skin care composition, or a feed composition.
  • the pharmaceutical composition may be in any suitable form, and is not particularly limited, and may be in a correspondingly suitable dosage form depending on the intended use.
  • the pharmaceutical composition may be administered orally or non-orally (e.g., transdermal, subcutaneous, intravenous) to a subject in need thereof.
  • a suitable carrier may be selected to provide the pharmaceutical composition, wherein the carrier comprises an excipient, a diluent, an adjuvant, a stabilizer, an absorption delaying agent, a disintegrating agent, and an increase Solvents, emulsifiers, antioxidants, binders, binders, tackifiers, dispersants, suspending agents, lubricants, moisture absorbents, and the like.
  • the pharmaceutical composition provided according to the present invention may contain any pharmaceutically acceptable carrier which does not adversely affect the desired benefits of the first component and the second component of the present invention.
  • any pharmaceutically acceptable carrier which does not adversely affect the desired benefits of the first component and the second component of the present invention.
  • the pharmaceutical composition may be provided in a dosage form suitable for oral administration by any convenient method, for example, a tablet (for example, a sugar-coated tablet), a pill, a capsule, a granule, a powder, a flow extract, a solution, a syrup , suspensions, tinctures, etc.
  • the pharmaceutical composition provided according to the present invention may be in the form of a patch, an emulsion, a cream, a gel (for example, a hydrogel), a paste (for example, dispersed) for direct external application.
  • one or more, for example, isotonic solutions, salt buffers (such as phosphate buffer or citrate) may be included in the pharmaceutical compositions provided according to the present invention.
  • the buffer solution, the solubilizer, the emulsifier, the 5% sugar solution, and other carriers are provided by the intravenous infusion solution, the emulsion intravenous infusion solution, the dry powder injection, the suspension injection, or the dry powder suspension injection.
  • the pharmaceutical composition can be prepared as a pre-injection solid, the pre-injection solid is provided in a dosage form, or emulsifiable, which is soluble in other solutions or suspensions, and prior to administration to an individual in need thereof, The solid prior to injection is dissolved in other solutions or suspensions or emulsified to provide the desired injectables.
  • compositions provided in accordance with the present invention may be administered at different dosing times, such as once a day, multiple times a day, or several times a day, depending on the individual's needs, age, weight, and health profile.
  • dosesing times such as once a day, multiple times a day, or several times a day, depending on the individual's needs, age, weight, and health profile.
  • the proportion of the first component and the second component in the composition is adjusted depending on the actual application requirements.
  • a pharmaceutical composition, a food composition, a cosmetic composition, a skin care composition, or a feed composition may further contain a suitable amount of an additive, for example, the pharmaceutical composition and the food may be improved.
  • a composition, a cosmetic composition, a skin care composition, or a flavoring agent, a toner, a coloring agent, etc. which are mouth-feeling and visually sensible at the time of administration, and which can improve the pharmaceutical composition, the food composition, A buffer, a preservative, a preservative, an antibacterial agent, an antifungal agent, and the like for the stability and storage stability of a cosmetic composition, a skin care composition, or a feed composition.
  • the food composition provided according to the present invention may be a health food, a health food, a functional food, a nutritional supplement or a special nutritious food, and may be made into, for example, dairy products, meat processed products, breads, noodles, biscuits, Ingots, capsules, juices, teas, sports drinks, nutritional drinks, soups, powders, jellies, soft candy, solid-liquid mixed soups, or solid-liquid mixed drinks, etc., but not limited to this.
  • the health food, health food, functional food, nutritional supplement food and special nutritious food provided according to the present invention can be eaten at different frequencies once a day, once a day, or several times a day, depending on the age and weight of the individual. And health conditions vary.
  • the content of the first component and the second component in the health food, the health food, the functional food, the nutritional supplement food and the special nutritious food provided according to the present invention may also be adjusted for a specific ethnic group, preferably adjusted to a daily basis. The amount taken.
  • the cosmetic composition and skin care composition provided according to the present invention can be used for at least one of improving endurance performance, improving exercise capacity, enhancing physical strength, restoring physical strength, promoting fatigue elimination, preventing myocardial weakness, and helping the heart to improve, And help the heart function improve.
  • the skin care composition provided in accordance with the present invention may be in any convenient form and is not particularly limited.
  • the skin care composition may be in the form of an emulsion, a cream, a gel (for example, a hydrogel), or a solution (for example, an essence, a lotion) for direct external use, but is not limited thereto.
  • the cosmetic or skin care composition provided according to the present invention When applying the cosmetic or skin care composition provided according to the present invention to improve endurance performance, improve exercise capacity, enhance physical strength, restore physical strength, promote fatigue elimination, prevent myocardial weakness, help heart weakness, and/or help cardiac function
  • the content of the first component and the second component may be different depending on the product type.
  • the feed composition provided according to the present invention may contain any other edible material which does not adversely affect the desired benefits of the first component and the second component of the present invention, for example, an emulsifier, a skim milk powder, a soy protein, Salts such as sugars, starches, processed starches, dextrin, inorganic salts or organic salts.
  • the feed composition can be provided in the form of a solid, liquid, emulsified state, or the like, by any convenient method.
  • the present invention also provides a method of anti-fatigue comprising administering an effective amount of a composition to an individual in need thereof, wherein the composition comprises as a first component a Cistanche tubulosa extract and as The second component is an oxidized coenzyme (Q10) and/or a reduced coenzyme (QH).
  • the protocols, routes of administration, form of administration, frequency of administration, and related applications of the compositions are as described above.
  • the crude extract is dissolved by heating with 1 volume of water of the crude extract, and the solution is injected into the macroporous adsorption resin column, and sequentially washed with 4 volumes of water and 10 volumes of 40% ethanol of the column. Dissolve, and then inject the water eluent into the macroporous adsorption resin column, sequentially elute with 3 times volume of water and 4 times volume of 40% ethanol in the column, discard the water eluent and collect twice. After the % ethanol eluate, it was concentrated and dried to obtain a dried product (i.e., Cistanche tubulosa extract), about 1.1 kg.
  • a dried product i.e., Cistanche tubulosa extract
  • TNF- ⁇ tumor necrosis factor alpha
  • OCR oxygen consumption rate
  • ECAR extracellular acidification rate
  • C2C12 cells i.e., mouse myocytes, purchased from ATCC
  • H-DMEM medium purchased from Sigma
  • 10% fetal bovine serum purchased from BI Corporation
  • the cells were divided into seventeen groups (one control group, one TNF- ⁇ group, and fifteen experimental groups). And do the following:
  • Control group cultured in H-DMEM medium for 6 hours. Next, the medium was changed to a differentiation medium (H-DMEM medium + 2% horse serum), and the culture was continued for 4 days.
  • H-DMEM medium + 2% horse serum a differentiation medium
  • TNF- ⁇ group cultured in H-DMEM medium for 6 hours. Next, the medium was changed to a differentiation medium (H-DMEM medium + 2% horse serum), and TNF- ⁇ was added thereto to have a final concentration of 10 ng/ml in the medium, and the cultivation was continued until overnight. Finally, the medium was changed to a differentiation medium and cultured for another 4 days.
  • a differentiation medium H-DMEM medium + 2% horse serum
  • Groups 1 to 15 of the experimental group Culture was carried out in H-DMEM medium, and 0.4 ⁇ l of the composition shown in Table 1 was added to each group of the medium for 6 hours. Next, the medium was changed to a differentiation medium (H-DMEM medium + 2% horse serum), and 0.4 ⁇ l of the composition shown in Table 1 and TNF- ⁇ were added, respectively (to make TNF- ⁇ in the medium) The final concentration was 10 ng/ml) and continued to grow overnight. Finally, the medium was changed to a differentiation medium, and 0.4 ⁇ l of the composition shown in Table 1 was added to each group of the medium, followed by further culture for 4 days. In Table 1, "micrograms/ml” indicates the weight of the extract (by dry weight) and/or reduced coenzyme (by dry weight) contained per ml of the medium.
  • the control group, the TNF- ⁇ group, and the experimental group 1 to 15 cells provided in the above Example (1-1) were taken, and the cell oxygen consumption rate of each group was measured by a cell energy metabolism analyzer (Seahorse XF24). (Including ATP to produce oxygen consumption and maximum respiratory oxygen consumption), based on the results of the control group (ie, the cell oxygen consumption rate of the control group was set to 1 time), the cell oxygen consumption rate of each group was calculated. The results are shown in Figures 1A and 1B.
  • composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component
  • the composition in which the weight ratio of the first component to the second component is from 0.67:1 to 10:1 can effectively slow down the decrease of the cell oxygen consumption rate induced by TNF- ⁇ , so it has anti-fatigue effect.
  • control group, the TNF- ⁇ group, and the experimental group 1 to 8 cells provided in the above Example (1-1) were taken, and the extracellular acidity of each group was measured by a cell energy metabolism analyzer (including glycolysis).
  • the solution level and glycolysis reserve were calculated based on the results of the control group (ie, the extracellular acidity of the control group was set to 1 time), and the extracellular acidity of each group was calculated.
  • the results are shown in Figures 2A and 2B.
  • composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component
  • the composition in which the weight ratio of the first component to the second component is from 0.67:1 to 10:1 can effectively alleviate the abnormality of extracellular acidity induced by TNF- ⁇ , so it has anti-fatigue effect.
  • animal endurance, muscle strength, and blood biochemical values were used in animal models (including: serum lactate, serum ammonia, serum free fatty acid, and serum glucose). ), evaluation of fatigue indicators such as creatine kinase (CK) activity in blood.
  • CK creatine kinase
  • blood lactic acid, blood ammonia, and blood creatine kinase are metabolites produced after exercise, and therefore, the rise of these biochemical values indicates an increase in the degree of fatigue of mice.
  • the free fatty acids in the blood and blood sugar represent the reserve energy of the mice. Therefore, the rise of these biochemical values indicates that the degree of fatigue of the mice is decreased.
  • ICR mice Eight-week-old male ICR mice (purchased from Lesco Biotech Co., Ltd., with an average body weight of about 25 to 30 grams) were divided into four groups of six each. Feeding for 14 days under a 12-hour day to 12-hour cycle (no restriction on diet, but feeding the composition shown in Table 2 once a day by tube irrigation):
  • the weight ratio of the extract to the reduced coenzyme (extract: reduced coenzyme) in the composition fed from the above Group I to Group III is shown in Table 3 below.
  • Carrier group Group I Group II Group III Extract weight ratio of reduced coenzyme - 1.67:1 3.33:1 6.67:1
  • Example (2-1) To the back of each group of mouse models established in Example (2-1), a lead wire having a weight of about 5 percent of its body weight was attached to the weight-bearing swimming.
  • the aforementioned weight-bearing swimming forced the mice to swim in a glass water tank with a water temperature of about 27 ° C, and recorded the time from the start of swimming to the time when the head was completely in the water for 8 seconds and could not rise to the surface (ie, exhaustion time). ), the results are shown in Figure 3.
  • the exhaustion time of the mice of the first to third groups was significantly increased as compared with the vehicle group, and the increase in the exhaustion time of the mice of the second group was most remarkable.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can really improve the endurance performance of mice, improve their athletic ability and enhance their physical strength.
  • Example (2-1) Each group of mouse models established in Example (2-1) was subjected to a forelimb grip test using a grip tester (available from Engineering, Nagoya, Japan) to understand the effect of the composition of the present invention on muscle strength. .
  • the results are shown in Figure 4.
  • the forelimb grip strength of the mice of the first to third groups was significantly improved as compared with the vehicle group.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can really improve the muscle performance of mice, improve their athletic ability and enhance their physical strength.
  • Example (2-1) Each group of mouse models established in Example (2-1) was subjected to swimming exercise for 15 minutes. Next, blood was collected from the orbits of each mouse for use.
  • lactate oxidase was added to the blood of each group of mice provided in Example (2-4), followed by the addition of 4-amine antipyrine (4 -aminoantipyrine) and 1,7-dihydroxynaphthalene. After the red compound is produced by the action of the peroxidase, the absorbance is measured at a wavelength of 540 nm, and then converted to the concentration of lactic acid in the blood. The results are shown in Figure 5A.
  • the blood lactate values of the mice in the first to third groups were significantly decreased as compared with the vehicle group.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can really reduce the metabolites after exercise in the blood of mice, and has the effect of reducing the degree of fatigue of mice, which helps to restore physical strength and promote fatigue elimination.
  • bromophenol blue was added as a coloring agent to the blood of each group of mice provided in Example (2-4), and after the blue compound was formed, the wavelength was 605 nm. The absorbance is measured and converted to blood ammonia concentration. The results are shown in Figure 5B.
  • the blood ammonia levels of the mice of the first to third groups were significantly decreased as compared with the vehicle group.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can really reduce the metabolites after exercise in the blood of mice, and has the effect of reducing the degree of fatigue of mice, which helps to restore physical strength and promote fatigue elimination.
  • acyl CoA synthetase and acyl CoA oxidase were added to the blood of each group of mice provided in Example (2-4). And peroxidase. After the purple compound is reacted, the absorbance is measured at a wavelength of 550 nm and converted to the concentration of free fatty acids in the blood. The results are shown in Figure 5C.
  • the blood free fatty acid values of the mice of Groups II and III were significantly increased compared to the vehicle group.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can indeed increase the reserve energy in the blood of mice, and has the effect of reducing the degree of fatigue of mice, which helps to restore physical strength and promote fatigue elimination.
  • glucose oxidase was added to the blood of each group of mice provided in Example (2-4), followed by addition of 4-amine antipyrine and 1 , 7-dihydroxynaphthalene. After the red compound is produced by the action of the oxidase, the absorbance is measured at a wavelength of 555 nm, and then converted into a blood glucose concentration. The results are shown in Figure 5D.
  • the blood glucose levels of the mice of Groups I and II were significantly increased compared to the vehicle group.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can indeed increase the reserve energy in the blood of mice, and has the effect of reducing the degree of fatigue of mice, which helps to restore physical strength and promote fatigue elimination.
  • creatine phosphate glucose oxidase was added to the blood of each group of mice provided in Example (2-4), followed by addition of 4-amine Tebulin and 1,7-dihydroxynaphthalene. After the white compound is produced by the action of the oxidase, the absorbance is measured at a wavelength of 680 nm, and then converted into the concentration of creatine kinase in the blood. The results are shown in Figure 5E.
  • the blood creatine kinase values of the mice of the first to third groups were significantly decreased as compared with the vehicle group.
  • the foregoing results show that the composition of the present invention having the Cistanche tubulosa extract as the first component and the oxidized coenzyme (Q10) and/or the reduced coenzyme (QH) as the second component It can really reduce the metabolites after exercise in the blood of mice, and has the effect of reducing the degree of fatigue of mice, which helps to restore physical strength and promote fatigue elimination.
  • the extract of Cistanche tubulosa of the present invention is the first component, and the oxidized coenzyme (Q10) and/or reduced coenzyme (QH) are the second component.
  • the composition especially the composition in which the weight ratio of the first component to the second component is from 0.67:1 to 10:1, can effectively slow down the oxygen consumption of ATP induced by TNF- ⁇ and the decrease of maximum respiratory oxygen consumption. And can slow down the level of glycolysis induced by TNF- ⁇ , thereby increasing the cell's glycolysis reserve.
  • the composition of the present invention can enhance the endurance and muscle strength of mice, reduce blood metabolites after exercise, and increase the reserve energy of mice after exercise.
  • the composition of the present invention has an anti-fatigue effect, and thus can be used for at least one of: treating chronic fatigue syndrome, preventing chronic fatigue syndrome, improving endurance performance, improving exercise capacity, enhancing physical strength, restoring physical strength, promoting fatigue elimination, and prevention.
  • Myocardial weakness help the heart to improve, and help improve heart function.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种组合物包含第一组分---管花肉苁蓉萃取物以及第二组分---氧化型辅酵素(Q10)和/或还原型辅酵素(QH)。两个组分的重量比为：第一组分：第二组分＝0.67：1至10：1。该组合物为医药组合物、食品组合物、化妆品组合物、保健品组合物或饲料组合物。该医药组合物可用于治疗或预防慢性疲劳症候群。该食品组合物、化妆品组合物、保健品组合物或饲料组合物可用于以下至少一种情形：提高耐力或运动力、增强或恢复体力、消除疲劳、预防心肌无力、改善心脏无力或心脏机能。

Description

提高耐力表现的抗疲劳组合物 技术领域
本发明关于一组合物，其包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)。本发明也关于该组合物于抗疲劳的应用，尤其关于该组合物于以下至少一者的应用：治疗慢性疲劳症候群、预防慢性疲劳症候群、提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。于前述组合物中，该第一组分与该第二组分的重量比为第一组分：第二组分＝0.67：1至10：1。
背景技术
所谓疲劳(fatigue)，是指身体的生理功能无法维持在一定水平上的运作及/或器官(例如心脏)无法保持其原本的工作能力，而导致运动能力及体力下降。然而，若长时间处于过度压力或过度劳动的状况，会使得身体无法充分获得休息，而无法消除疲劳感或倦怠感。疲劳感或倦怠感是身体发出的警讯，一般而言，可通过使身体休息而消除。然而，若长时间处于过度压力或过度劳动的状况，会使得身体无法充分获得休息，长期下来可能产生激烈的全身疲劳感，同时引起淋巴节肿胀、轻微发热、头痛、肌肉痛、关节痛、思考力降低、集中力降低、睡眠障碍等慢性疲劳症候群(Chronic Fatigue Syndrome，CFS)的症状，严重时可能导致心肌无力、心脏机能低下，甚至可能发生意外事故、危及个人生命。因此，持续开发可有效抗疲劳的方法或药物，以降低耗用在疲劳所导致伤病的社会成本，乃有其必要性。
中药肉苁蓉(Herba Cistanches)最早被记载于《神农本草经》，是肉 苁蓉属列当科(Orobanchaceae)多年生寄生草本植物中的一种，其依靠吸取寄主植物红柳的养分生活，并分布于沙漠、荒漠等干燥地带，为一种贵重而罕见的肉苁蓉药材。氧化型辅酵素(Q10)主要存在于真核细胞的线粒体中，其作为电子传递链的辅酵素并参与细胞的有氧呼吸作用，可促进ATP生成以供应细胞所需的能量。还原型辅酵素(QH)则为氧化型辅酵素(Q10)的还原型，其不需通过体内转换便能够被人体直接吸收、利用，故其生物利用率较氧化型辅酵素(Q10)高。
本发明发明人研究发现一能够提供优异的抗疲劳效果的组合物，该组合物包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)，其中该第一组分与该第二组分的重量比为第一组分：第二组分＝0.67：1至10：1，该组合物可应用于以下的至少一者：治疗慢性疲劳症候群、预防慢性疲劳症候群、提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。本发明通过上述第一组分与第二组分的并用，可在相对低廉的制造成本下提供具优异效果的抗疲劳的组合物，深具经济效益。
发明内容
本发明的一目的，在于提供一种组合物，其包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)，其中该第一组分与该第二组分的重量比为第一组分：第二组分＝0.67：1至10：1。较佳地，该管花肉苁蓉萃取物为管花肉苁蓉的极性溶剂萃取物，其中该极性溶剂选自水、C1-C4醇类、及前述的组 合。
较佳地，根据本发明所提供的组合物还包含以下的至少一者：维生素B群、红景天(Rhodiola rosea)萃取物、五味子(Schisandra chinensis)萃取物、维生素E、核糖、山楂萃取物、镁、钙、鱼油、牛磺酸、鸡精、刺五加萃取物、人参萃取物、蚬精、冬虫夏草萃取物、大豆分离蛋白、BCAA(支链胺基酸)、肉酸、异麦芽酮糖、葡萄糖、益生菌、乳清蛋白、牛奶分离蛋白、GABA(γ-胺基丁酸)、天麻萃取物、L-色胺酸、及γ-谷维素。更佳地，该组合物还包含选自以下群组的一者：维生素B1、维生素B1的衍生物、维生素B6、维生素B6的衍生物、及前述的组合。
较佳地，根据本发明所提供的组合物为一抗疲劳的医药组合物、食品组合物、化妆品组合物、保养品组合物、或饲料组合物。其中，于根据本发明所提供的医药组合物的一具体实施方案，该医药组合物用于治疗或预防慢性疲劳症候群。较佳地，该医药组合物呈口服、经皮、静脉注射、或皮下注射的剂型。
较佳地，根据本发明所提供的抗疲劳食品组合物、化妆品组合物、保养品组合物、或饲料组合物用于以下的至少一者：提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。该食品组合物可以为健康食品、保健食品、机能性食品、营养补充食品或特殊营养食品，较佳地，该食品组合物为一乳制品、肉类加工品、面包类、面食品、饼干、口含锭、胶囊、果汁类、茶类、运动饮料、营养饮料、汤汁、粉末、果冻、软糖、固液混合汤品、或固液混合饮品。
本发明的另一目的，在于提供一种抗疲劳的方法，其包含对一有需要的个体投予一有效量的上述组合物。本发明方法可用于以下的至少一者：治疗慢性疲劳症候群、预防慢性疲劳症候群、提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。
本发明的详细技术内容及部分具体实施方案，将描述于以下内容中，以供本领域技术人员据以明了本发明的特征。
附图说明
图1A及图1B所示分别为肌细胞的线粒体ATP产生耗氧、及最大呼吸耗氧速率，都包括“控制组”、“TNF-α组”及“实验组第1至15组”的结果，其中“控制组”于不含TNF-α、管花肉苁蓉萃取物及还原型辅酵素的培养基中进行培养，“TNF-α组”于含有TNF-α、但不含管花肉苁蓉萃取物及还原型辅酵素的培养基中进行培养，“实验组第1至15组”则于含有TNF-α、管花肉苁蓉萃取物及/或还原型辅酵素的培养基中进行培养；
图2A及图2B所示分别为肌细胞的糖酵解水准及糖酵解储备，都包括上述“控制组”、“TNF-α组”及“实验组第1至15组”的结果；
图3所示为小鼠负重游泳的力竭时间，包括“载剂组”、“第I组”、“第II组”及“第III组”的结果，其中“载剂组”喂食仅含载剂的组合物(不含管花肉苁蓉萃取物及还原型辅酵素)，第I组小鼠喂食含有载剂及重量比为1.67：1(管花肉苁蓉萃取物：还原型辅酵素)的组合物，第II组小鼠喂食含有载剂及重量比为3.33：1(管花肉苁蓉萃取物：还原型辅酵素)的组合物，第III组小鼠喂食含有载剂及重量比为6.67：1(管花肉苁蓉萃取物：还 原型辅酵素)的组合物；
图4所示为小鼠负重游泳后的前肢抓力，包括上述“载剂组”、“第I组”、“第II组”及“第III组”小鼠的结果；以及
图5A至图5E所示为上述“载剂组”、“第I组”、“第II组”及“第III组”小鼠进行游泳运动后的血液生化值，其中，图5A显示血乳酸(serum lactate)，图5B显示血氨(serum ammonia)，图5C显示血中游离脂肪酸(serum free fatty acid)，图5D显示血糖(serum glucose)，以及图5E显示血中肌酸激酶(creatine kinase，CK)活性。
具体实施方式
本发明的详细技术及较佳实施方案，将描述于以下内容中，以供本领域技术人员据以明了本发明的特征；但在不背离本发明精神下，本发明还可以多种不同形式的方案来实践，不应将本发明保护范围解释为限于说明书所陈述的。此外，除非文中有另外说明，于本说明书中(尤其是在权利要求书中)所使用的“一”、“该”及类似用语应理解为包含单数及复数形式；所谓“有效量”，是指投予至个体时，可有效至少部分降低该个体的疲劳感或倦怠感、或改善该个体的慢性疲劳症候群的症状的剂量；所谓“个体”是指人类或非人的哺乳动物；所谓“预防”是指抑制或防止一具体病况的发作、或维持敏感个体的良好健康状态或建立该个体对疾病的耐受性；所谓“治疗”，不应被解释为治疗一个体直至完全恢复，而应包括将一个体的疾病进展或症状维持在一实质上静态的程度、增加一个体的恢复速率、降低一具体病况的严重性、或提高一患者的生命品质。
于本发明说明书中，组合物中所含组分的“重量比”以干重计；所谓“以 干重计”，是指将各组分(例如，第一组分、第二组分)以干燥物的状态进行秤重，而计算的所需用量；所谓“耐力表现”，是指肌肉在一阻力存在的情况下可以持续运作的期间长短。
本说明书中所使用的数值范围(例如5至100)应理解为也包含在该范围中的所有有理数以及在该范围中的任何有理数所组成的范围，因此，本说明书中所使用的数值范围包含介于所列举的最低值与最高值之间的数值的所有可能组合。另，当本文于数值前使用“约”时，实质上代表与所述数值相差在10％以内，较佳在5％以内。
如上述，长时间处于疲劳的状态，可能产生慢性疲劳症候群的症状，严重时可能导致心肌无力、心脏机能低下。本发明发明人研究发现，包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)的组合物，尤其是其中第一组分与第二组分的重量比为0.67：1至10：1的组合物，可有效减缓TNF-α所诱导的细胞耗氧速率下降、减缓TNF-α所诱导的细胞外产酸度异常、提升小鼠的耐力及肌力表现、降低小鼠运动后的血液中代谢产物、提供小鼠血液中的储备能量，故具有抗疲劳的效果。一般认为上述组合物可用于以下的至少一者：治疗慢性疲劳症候群、预防慢性疲劳症候群、提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。因此，本发明提供一种组合物，其包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)，其中该第一组分与第二组分的重量比为0.67：1至10：1，较佳为0.67：1至6.67：1，更佳为1.67： 1至6.67：1。
于根据本发明的组合物中，所包含的管花肉苁蓉萃取物可以是一萃取液或通过干燥该萃取液所提供的干燥物，其中，该萃取液是通过使用一极性溶剂以萃取管花肉苁蓉原料，所提供的萃取液。其中，该管花肉苁蓉原料可以是管花肉苁蓉的任何部位，举例言之，可使用管花肉苁蓉的茎部、花、或全株植物作为萃取原料。于根据本发明的一实施方案中，使用管花肉苁蓉的肉质茎作为萃取原料。所采用的极性溶剂可以是水、C1-C4醇类、或前述的组合。较佳地，使用水、乙醇、或其组合作为该极性溶剂。可视需要调整用于萃取的极性溶剂与管花肉苁蓉原料的用量比率，一般而言，极性溶剂的用量并无特殊限制，只要可使原料均匀分散即可。为尽可能达到最大的萃取效益，视需要地，可以相同或不同极性溶剂重复多次萃取管花肉苁蓉原料，并合并该多次萃取所得的萃取液，其后进行干燥。
于上述萃取步骤中，可视需要调整萃取时间以达到所欲的萃取程度。以采用水作为该萃取溶剂为例，通常为至少15分钟，较佳为至少30分钟，更佳为至少60分钟。此外，视需要地，可辅以例如煎煮、冷却、过滤、减压浓缩、树脂管柱层析等其它操作，以提升萃取效益。
本发明组合物所包含的作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)，可以由任何合宜的来源提供，举例言之，可由市面上购得、通过微生物发酵提供、或通过化学合成获得。例如，可自Kaneka公司购得氧化型辅酵素及还原型辅酵素。
根据本发明所提供的组合物，可视需要还包含一或多种其他活性成分或与含该一或多种其他活性成分的药物或食品并用，以进一步加强该组合物的 功效或增加制剂配方的运用灵活性与调配度，只要该其他活性成分对本发明第一组分及第二组分的效益没有不利的影响即可。该其他活性成分的例子包括，但不限于，维生素B群、红景天(Rhodiola rosea)萃取物、五味子(Schisandra chinensis)萃取物、维生素E、核糖、山楂萃取物、镁、钙、鱼油、牛磺酸、鸡精、刺五加萃取物、人参萃取物、蚬精、冬虫夏草萃取物、大豆分离蛋白、BCAA、肉酸、异麦芽酮糖、葡萄糖、益生菌、乳清蛋白、牛奶分离蛋白、GABA、天麻萃取物、L-色胺酸、以及γ-谷维素。较佳地，本发明组合物包含选自以下群组的一者：维生素B1、维生素B1的衍生物、维生素B6、维生素B6的衍生物、及前述的组合。
根据本发明所提供的组合物可以是一医药组合物、食品组合物、化妆品组合物、保养品组合物、或饲料组合物。其中，该医药组合物可呈任何合宜的型式，并无特殊限制，视所欲的用途而呈对应的合宜剂型。举例言之，但不以此为限，该医药组合物可以口服或非经口服(例如：经皮、皮下注射、静脉注射)的投药方式施用至有需要的个体上。其中，视使用形式及用途而定，可选用合宜的载剂以提供该医药组合物，其中，该载剂包括赋形剂、稀释剂、辅助剂、安定剂、吸收延迟剂、崩散剂、增溶剂、乳化剂、抗氧化剂、粘合剂、结合剂、增粘剂、分散剂、悬浮化剂、润滑剂、吸湿剂等。
以适于口服的剂型为例，于根据本发明所提供的医药组合物中可含有任何不会不利影响本发明第一组分及第二组分的所欲效益的医药上可接受的载剂，例如：水、食盐水、葡萄糖(dextrose)、甘油、乙醇或其类似物、纤维素、淀粉、糖膨润土(sugar bentonite)、及前述的组合。可利用任何合宜的方法，将该医药组合物以适于口服投药的剂型提供，例如：锭剂(例 如糖衣锭)、丸剂、胶囊剂、颗粒剂、散剂、流浸膏剂、溶液剂、糖浆剂、悬液剂、酊剂等。
以适于经皮投予的剂型为例，根据本发明所提供的医药组合物可呈供直接外用的贴布、乳液、乳霜、凝胶(例如水凝胶)、膏状物(例如分散膏、软膏)、喷雾剂、或溶液(例如悬浮液)等形式，但不以此为限。
至于适于皮下或静脉注射的针剂或点滴剂，则可于根据本发明所提供的医药组合物中含有一或多种例如等张溶液、盐类缓冲液(如磷酸盐缓冲液或柠檬酸盐缓冲液)、增溶剂、乳化剂、5％糖溶液、以及其他载剂等成分，以静脉输注液、乳剂静脉输注液、干粉注射剂、悬液注射剂、或干粉悬液注射剂等剂型提供该医药组合物。或者，可将该医药组合物制备成一注射前固体，以可溶于其他溶液或悬浮液中的剂型、或可乳化的剂型提供该注射前固体，并于投予至有需要的个体之前，将该注射前固体溶于其他溶液或悬浮液中或将其乳化，提供所欲的注射剂。
根据本发明所提供的医药组合物可以一日一次、一日多次、或数日一次等不同投药频率施用，视投予个体的需求、年龄、体重、及健康况状而异。于根据本发明所提供的医药组合物中，可视实际应用需求，调整第一组分及第二组分于组合物中的含量比例。
视需要地，可于根据本发明所提供的医药组合物、食品组合物、化妆品组合物、保养品组合物、或饲料组合物中另含有合宜用量的添加剂，例如可提高该医药组合物、食品组合物、化妆品组合物、保养品组合物、或饲料组合物于服用时的口适感及视觉感受的调味剂、调色剂、着色剂等，以及可改善该医药组合物、食品组合物、化妆品组合物、保养品组合物、或饲料组合 物的稳定性及储存性的缓冲剂、保存剂、防腐剂、抗菌剂、抗真菌剂等。
根据本发明所提供的食品组合物可以是健康食品、保健食品、机能性食品、营养补充食品或特殊营养食品，且可制成例如乳制品、肉类加工品、面包类、面食品、饼干、口含锭、胶囊、果汁类、茶类、运动饮料、营养饮料、汤汁、粉末、果冻、软糖、固液混合汤品、或固液混合饮品等产品，但不以此为限。
根据本发明所提供的健康食品、保健食品、机能性食品、营养补充食品及特殊营养食品可以一日一次、一日多次、或数日一次等不同频率食用，视投予个体的年龄、体重、及健康状况而异。也可针对特定族群调整根据本发明所提供的健康食品、保健食品、机能性食品、营养补充食品及特殊营养食品中第一组分及第二组分的含量，较佳为调整至每日应服用的量。
可于根据本发明所提供的健康食品、保健食品、机能性食品、营养补充食品及/或特殊营养食品的外包装标示建议使用量、特定族群(例如运动员、心脏病患者、糖尿病患者、孕妇、老人、肌少症患者等)的使用标准及条件、或与其他食品或医药共同服用的建议事项，以利使用者在无医师、药师或相关执事人员指导下可在家自行服用而无安全疑虑。
根据本发明所提供的化妆品组合物及保养品组合物系可用于以下的至少一者：提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。根据本发明所提供的保养品组合物可呈任何合宜的形式，并无特殊的限制。举例言之，该保养品组合物可呈供直接外用的乳液、乳霜、凝胶(例如水凝胶)、或溶液(例如精华液、化妆水)等形式，但不以此为限。
当施用根据本发明所提供的化妆品组合物或保养品组合物以提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及/或帮助心脏机能改善时，可视产品型态而含有不同的第一组分及第二组分的含量。
根据本发明所提供的饲料组合物中系可含有任何不会不利影响本发明第一组分及第二组分的所欲效益的其他可食用原料，例如：乳化剂、脱脂粉乳、大豆蛋白、糖类、淀粉、加工淀粉、糊精、无机盐或有机盐等盐类。可利用任何合宜的方法，将该饲料组合物以固体、液体、乳化状态等形式提供。
本发明也提供一种抗疲劳的方法，其包含对一有需要的个体投予一有效量的组合物，其中该组合物包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)。有关该组合物的方案、投予途径、投予形式、施用频率、以及相关的应用，均如上述的说明。
现以下列实施例进一步例示说明本发明。其中这些实施例仅提供作为说明，而非用以限制本发明的保护范围。本发明保护范围以权利要求书中的为准。
实施例
[制备实施例]：管花肉苁蓉萃取物(Cistanche tubulosa extract)的制备
取管花肉苁蓉的肉质茎部分10公斤，切片后加入其体积的8倍的水，浸泡1小时后，再煎煮2小时，过滤并收集滤液。加入药渣体积的6倍的水，煎煮2次，每次1小时，并过滤。合并三次滤液，于50℃下减压浓缩至比重1.10， 添加乙醇至浓度60％，冷藏12小时后倾出上清液，于50℃下减压浓缩并回收乙醇至比重1.10，获得粗萃取物6公斤。接着，以粗萃取物的1倍体积的水加热溶解粗萃取物，将溶液注入大孔吸附树脂柱内，依序以管柱4倍体积的水及管柱5倍体积的40％乙醇进行洗脱，再将水洗脱液注入大孔吸附树脂柱中，依序以管柱3倍体积的水及管柱4倍体积的40％乙醇洗脱，弃去水洗脱液，收集两次40％乙醇洗脱液后，再进行浓缩干燥，以获得一干燥物(即，管花肉苁蓉萃取物)，约1.1公斤。
实施例1：细胞实验
(1-1)细胞处理
已知一个体的激烈或长时间运动会造成肿瘤坏死因子-α(tumor necrosis factor alpha，TNF-α)的大量释放，造成包括细胞耗氧速率(oxygen consumption rate(OCR)，其反应线粒体的有氧代谢能力)及细胞外产酸度(extracellular acidification rate(ECAR)，其反应线粒体的糖酵解能力)等线粒体功能的下降，于此情况下，线粒体将无法产生足够的ATP供细胞使用，而使该个体产生疲劳的状况。本实施例对经TNF-α诱导损伤的C2C12肌细胞，投予本发明的包含管花肉苁蓉萃取物及还原型辅酵素的组合物，以了解本发明组合物于抗疲劳的效果。
首先，以含有10％胎牛血清(购自BI公司)的H-DMEM培养基(购自Sigma公司)对C2C12细胞(即，小鼠的肌细胞，购自ATCC)进行培养。待C2C12细胞生长至80％汇合度(即，混合单层细胞占80％面积)后，将细胞分成十七组(一组控制组、一组TNF-α组、及十五组实验组)，并进行以下处理：
1.控制组：以H-DMEM培养基进行培养，历时6小时。接着，将培养基更换为分化培养基(H-DMEM培养基+2％马血清)，继续培养4天。
2.TNF-α组：以H-DMEM培养基进行培养，历时6小时。接着，将培养基更换为分化培养基(H-DMEM培养基+2％马血清)，并加入TNF-α使其于培养基中的最终浓度为10纳克/毫升，继续培养至隔夜。最后，将培养基更换为分化培养基，再培养4天。
3.实验组第1至15组：以H-DMEM培养基进行培养，并于各组的培养基中分别加入0.4微升的表1所示的组合物，历时6小时。接着，将培养基更换为分化培养基(H-DMEM培养基+2％马血清)，并分别加入0.4微升的表1所示的组合物以及TNF-α(使TNF-α于培养基中的最终浓度为10纳克/毫升)，继续培养至隔夜。最后，将培养基更换为分化培养基，并于各组的培养基中分别加入0.4微升的表1所示的组合物，再培养4天。其中，表1中，以“微克/毫升”表示每毫升培养基中，所含的萃取物(以干重计)及/或还原型辅酵素(以干重计)的重量。
表1
Figure PCTCN2018076630-appb-000001
Figure PCTCN2018076630-appb-000002
(1-2)包含管花肉苁蓉萃取物及还原型辅酵素的组合物对细胞耗氧速率的影响
取上述实施例(1-1)所提供的控制组、TNF-α组、及实验组第1至15组的细胞，并以细胞能量代谢分析仪(Seahorse XF24)测定各组的细胞耗氧速率(包含ATP产生耗氧及最大呼吸耗氧)，以控制组的结果为基准(即，将控制组的细胞耗氧速率设定为1倍)，计算各组的细胞耗氧速率。结果示于图1A及图1B。
由图1A及图1B可知，相较于控制组，TNF-α组的ATP产生耗氧及最大呼吸耗氧都显著下降，显示TNF-α确实可以有效抑制线粒体的呼吸能力(可借 以模拟疲劳的状况)。其中，由实验组第9至12组的结果可知，单独投予还原型辅酵素并不能减缓TNF-α所诱导的ATP产生耗氧及最大呼吸耗氧下降。由实验组第1至8组的结果则可知，合并投予管花肉苁蓉萃取物及还原型辅酵素可有效减缓TNF-α所诱导的ATP产生耗氧及最大呼吸耗氧下降，其中，又以使用重量比为0.67：1至10：1(萃取物：还原型辅酵素)的组合(即，实验组第3至8组)时的效果为较佳。
前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，尤其是其中第一组分与第二组分的重量比为0.67：1至10：1的组合物，确实可以有效减缓TNF-α所诱导的细胞耗氧速率下降，故具有抗疲劳的效果。
(1-3)包含管花肉苁蓉萃取物及还原型辅酵素的组合物对细胞外产酸度的影响
取上述实施例(1-1)所提供的控制组、TNF-α组、及实验组第1至8组的细胞，并以细胞能量代谢分析仪测定各组的细胞外产酸度(包含糖酵解水准及糖酵解储备)，以控制组的结果为基准(即，将控制组的细胞外产酸度设定为1倍)，计算各组的细胞外产酸度。结果示于图2A及图2B。
由图2A及图2B可知，相较于控制组，TNF-α组的糖酵解水准显著上升、且糖酵解储备显著下降，显示TNF-α确实可有效提高细胞的糖酵解水准，并降低细胞的糖酵解储备(可借此模拟疲劳的状况)。由实验组第1至8组的结果可知，合并投予管花肉苁蓉萃取物及还原型辅酵素可有效减缓TNF-α所诱导的糖酵解水准上升、及糖酵解储备下降，其中，又以使用重量比为0.67： 1至10：1(萃取物：还原型辅酵素)的组合(即，实验组第3至8组)时的效果为较佳。
前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，尤其是其中第一组分与第二组分的重量比为0.67：1至10：1的组合物，确实可以有效减缓TNF-α所诱导的细胞外产酸度异常，故具有抗疲劳的效果。
实施例2：动物实验
本实施例以动物模型进行小鼠耐力、肌力、及血液生化值(包括：血乳酸(serum lactate)、血氨(serum ammonia)、血中游离脂肪酸(serum free fatty acid)、血糖(serum glucose)、血中肌酸激酶(creatine kinase，CK)活性)等疲劳指标的评估。已知血乳酸、血氨、及血中肌酸激酶都为运动后所产生的代谢产物，因此，前述这些生化数值的上升代表小鼠的疲劳程度上升。血中游离脂肪酸、及血糖则代表小鼠的储备能量，因此，前述这些生化数值的上升代表小鼠的疲劳程度下降。
(2-1)动物模型的建立
将8周龄的雄性ICR小鼠(购自乐斯科生物科技股份有限公司，平均体重约25至30克)分成四组，每组6只。在12小时日-12小时夜的循环下饲养14天(不限制饮食，但分别以管灌方式每日喂食表2所示的组合物一次)：
表2
Figure PCTCN2018076630-appb-000003
Figure PCTCN2018076630-appb-000004
于上述第I组至第III组所喂食的组合物中，萃取物与还原型辅酵素的重量比(萃取物：还原型辅酵素)为下表3所示。
表3
  载剂组 第I组 第II组 第III组
萃取物：还原型辅酵素的重量比 - 1.67：1 3.33：1 6.67：1
(2-2)包含管花肉苁蓉萃取物及还原型辅酵素的组合物对小鼠耐力表现的影响
分别于实施例(2-1)所建立的各组小鼠模型的背部绑上重量约为其体重的百分之五的铅丝，进行负重游泳。前述负重游泳在水温约27℃的玻璃水缸中强迫小鼠进行游泳运动，并纪录小鼠从开始进行游泳运动至头部全部入水持续8秒不能浮出水面为止的时间(即，力竭时间)，结果示于图3。
由图3可知，相较于载剂组，第I至III组小鼠的力竭时间明显增加，其 中，又以第II组小鼠的力竭时间的增加最为明显。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，确实可以提升小鼠的耐力表现、提高运动能力、增强体力。
(2-3)包含管花肉苁蓉萃取物及还原型辅酵素的组合物对小鼠肌力表现的影响
使用抓力测试仪(购自Engineering,Nagoya,Japan)，分别对实施例(2-1)所建立的各组小鼠模型进行前肢抓力测试，以了解本发明组合物对肌力表现的影响。结果示于图4。
由图4可知，相较于载剂组，第I至III组小鼠的前肢抓力都明显提升。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，确实可以提升小鼠的肌力表现、提高运动能力、增强体力。
(2-4)包含管花肉苁蓉萃取物及还原型辅酵素的组合物对小鼠血液生化值的影响
分别使实施例(2-1)所建立的各组小鼠模型进行游泳运动，历时15分钟。接着，自各小鼠的眼窝采血备用。
(2-4-1)血乳酸值的变化
利用酵素作用与比色测定的原理，于实施例(2-4)所提供的各组小鼠的血液中加入乳酸氧化酶(lactate oxidase)进行反应，接着加入4-胺安替比林(4-aminoantipyrine)及1,7-二羟萘(1,7-dihydroxynaphthalene)。待氧化酶(peroxidase)作用产生红色化合物后，于540纳米波长下测定其 吸光度，再换算成血液中的乳酸浓度。结果示于图5A。
由图5A可知，相较于载剂组，第I至III组小鼠血乳酸值都明显下降。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，确实可以降低小鼠血中运动后的代谢产物，具有降低小鼠疲劳程度的效果，有助于恢复体力、促进疲劳消除。
(2-4-2)血氨值的变化
利用比色测定的原理，于实施例(2-4)所提供的各组小鼠的血液中加入溴酚蓝(bromphenol blue)作为呈色剂，待作用产生蓝色化合物后，于605纳米波长下测定其吸光度，再换算成血氨浓度。结果示于图5B。
由图5B可知，相较于载剂组，第I至III组的小鼠血氨值都明显下降。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，确实可以降低小鼠血中运动后的代谢产物，具有降低小鼠疲劳程度的效果，有助于恢复体力、促进疲劳消除。
(2-4-3)血中游离脂肪酸值的变化
利用酵素作用与比色测定的原理，于实施例(2-4)所提供的各组小鼠的血液中加入酰基辅酶A合成酶(acyl CoA synthetase)、酰基辅酶A氧化酶(acyl CoA oxidase)及过氧化酶。待作用产生紫色化合物后，于550纳米波长下测定其吸光度，再换算成血液中游离脂肪酸的浓度。结果示于图5C。
由图5C可知，相较于载剂组，第II及III组的小鼠血中游离脂肪酸值都明显上升。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa) 萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，确实可以提高小鼠血中的储备能量，具有降低小鼠疲劳程度的效果，有助于恢复体力、促进疲劳消除。
(2-4-4)血糖值的变化
利用酵素作用及比色测定的原理，于实施例(2-4)所提供的各组小鼠的血液中加入葡萄糖氧化酶(glucose oxidase)进行反应，接着加入4-胺安替比林及1,7-二羟萘。待氧化酶作用产生红色化合物后，于555纳米波长下测定其吸光度，再换算成血糖浓度。结果示于图5D。
由图5D可知，相较于载剂组，第I及II组的小鼠血糖值都明显上升。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，确实可以提高小鼠血中的储备能量，具有降低小鼠疲劳程度的效果，有助于恢复体力、促进疲劳消除。
(2-4-5)血中肌酸激酶值的变化
利用酵素作用及比色测定的原理，于实施例(2-4)所提供的各组小鼠的血液中加入磷酸肌酸葡萄糖氧化酶(creatine phosphate glucose oxidase)进行反应，接着加入4-胺安替比林及1,7-二羟萘。待氧化酶作用产生白色化合物后，于680纳米波长下测定其吸光度，再换算成血液中肌酸激酶的浓度。结果示于图5E。
由图5E可知，相较于载剂组，第I至III组的小鼠血中肌酸激酶值都明显下降。前述结果显示，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第 二组分的组合物，确实可以降低小鼠血中运动后的代谢产物，具有降低小鼠疲劳程度的效果，有助于恢复体力、促进疲劳消除。
由以上实验结果可知，本发明的以管花肉苁蓉(Cistanche tubulosa)萃取物为第一组分、且以氧化型辅酵素(Q10)及/或还原型辅酵素(QH)为第二组分的组合物，尤其是其中第一组分与第二组分的重量比为0.67：1至10：1的组合物，确实可有效减缓TNF-α所诱导的ATP产生耗氧及最大呼吸耗氧下降，且可减缓TNF-α所诱导的细胞的糖酵解水准上升，从而提升细胞的糖酵解储备。此外，本发明组合物可以提升小鼠的耐力及肌力，并降低小鼠运动后的血中代谢产物、及提升小鼠运动后的储备能量。因此，本发明组合物确实具有抗疲劳的效果，故可用于以下至少一者：治疗慢性疲劳症候群、预防慢性疲劳症候群、提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。

Claims (10)

  1. 一种组合物，其特征在于：其包含作为第一组分的管花肉苁蓉(Cistanche tubulosa)萃取物以及作为第二组分的氧化型辅酵素(Q10)及/或还原型辅酵素(QH)，其中该第一组分与该第二组分的重量比为第一组分：第二组分＝0.67：1至10：1。
  2. 如权利要求1所述的组合物，其特征在于：该管花肉苁蓉萃取物为管花肉苁蓉的极性溶剂萃取物，该极性溶剂选自水、C1-C4醇类、及前述的组合。
  3. 如权利要求1所述的组合物，其特征在于：还包含以下的至少一者：维生素B群、红景天(Rhodiola rosea)萃取物、五味子(Schisandra chinensis)萃取物、维生素E、核糖、山楂萃取物、镁、钙、鱼油、牛磺酸、鸡精、刺五加萃取物、人参萃取物、蚬精、冬虫夏草萃取物、大豆分离蛋白、BCAA、肉酸、异麦芽酮糖、葡萄糖、益生菌、乳清蛋白、牛奶分离蛋白、GABA、天麻萃取物、L-色胺酸、及γ-谷维素。
  4. 如权利要求1所述的组合物，其特征在于：还包含选自以下群组的一者：维生素B1、维生素B1的衍生物、维生素B6、维生素B6的衍生物、或前述的组合。
  5. 如权利要求1至4中任一项所述的组合物，其特征在于：其为一抗疲劳的医药组合物、食品组合物、化妆品组合物、保养品组合物、或饲料组合物。
  6. 如权利要求5所述的组合物，其特征在于：该组合物为医药组合物，且该医药组合物用于治疗或预防慢性疲劳症候群。
  7. 如权利要求6所述的组合物，其特征在于：该医药组合物呈口服、经皮、静脉注射、或皮下注射的剂型。
  8. 如权利要求5所述的组合物，其特征在于：该组合物为食品组合物、化妆品组合物、保养品组合物、或饲料组合物，且用于以下的至少一者：提高耐力表现、提高运动能力、增强体力、恢复体力、促进疲劳消除、预防心肌无力、帮助心脏无力改善、及帮助心脏机能改善。
  9. 如权利要求8所述的组合物，其特征在于：该食品组合物为健康食品、保健食品、机能性食品、营养补充食品或特殊营养食品。
  10. 如权利要求9所述的组合物，其特征在于：该食品组合物为一乳制品、肉类加工品、面包类、面食品、饼干、口含锭、胶囊、果汁类、茶类、运动饮料、营养饮料、汤汁、粉末、果冻、软糖、固液混合汤品、或固液混合饮品。
PCT/CN2018/076630 2017-02-13 2018-02-13 提高耐力表现的抗疲劳组合物 Ceased WO2018145664A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2019004642A MY192107A (en) 2017-02-13 2018-02-13 Anti-fatigue composition for use in improving endurance performance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458304P 2017-02-13 2017-02-13
US62/458,304 2017-02-13

Publications (1)

Publication Number Publication Date
WO2018145664A1 true WO2018145664A1 (zh) 2018-08-16

Family

ID=63107192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/076630 Ceased WO2018145664A1 (zh) 2017-02-13 2018-02-13 提高耐力表现的抗疲劳组合物

Country Status (5)

Country Link
US (1) US10485836B2 (zh)
CN (1) CN108420854B (zh)
MY (1) MY192107A (zh)
TW (2) TWM565575U (zh)
WO (1) WO2018145664A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4333865A4 (en) * 2021-05-06 2025-01-15 Sinphar Tian-li Pharmaceutical Co., Ltd. (Hangzhou) USE OF AN EXTRACT OF CISTANCHE TUBULOSA IN THE PREPARATION OF A MEDICATION FOR RELIEVING KERATOCONJUNCTIVITIS SCIENCE

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107267595A (zh) * 2017-07-19 2017-10-20 王贤俊 一种肌酸激酶同工酶检测试剂的制备方法
TW201934132A (zh) 2018-02-13 2019-09-01 元進莊企業股份有限公司 禽類粗蛋白萃取物用於製備抗疲勞之組合物的用途
CN109761861A (zh) * 2018-12-29 2019-05-17 河北农业大学 一种从章鱼肝脏中提取牛磺酸的方法
CN112515164A (zh) * 2020-10-22 2021-03-19 宁波君瑞生物科技有限公司 一种增强耐力的液体制剂
IT202100011084A1 (it) * 2021-04-30 2022-10-30 Pharmanutra S P A Composizione nutraceutica per uso nel trattamento della stanchezza cronica/fatigue post covid-19
CN114916596A (zh) * 2022-03-15 2022-08-19 赵歆 具有抗疲劳功效和提高食欲功效的中药茶饮
CN118436766B (zh) * 2024-07-08 2024-09-17 天津捷昂康生物科技发展有限公司 一种大鲵肽组合物及制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012067023A (ja) * 2010-09-22 2012-04-05 Fancl Corp コウバクニクジュヨウエキスを含有する生体機能改善用組成物
CN105233274A (zh) * 2015-09-30 2016-01-13 孟令刚 一种包含肉苁蓉和酵素的口服组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008062559A1 (en) * 2006-11-22 2008-05-29 Asahi Kasei Pharma Corporation Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic
CN104605348A (zh) * 2015-01-09 2015-05-13 北京博远欣绿科技股份有限公司 含有管花肉苁蓉提取物的保健品及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012067023A (ja) * 2010-09-22 2012-04-05 Fancl Corp コウバクニクジュヨウエキスを含有する生体機能改善用組成物
CN105233274A (zh) * 2015-09-30 2016-01-13 孟令刚 一种包含肉苁蓉和酵素的口服组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TU, PENGFEI ET AL.: "Review on the Research Progress and Industry Development of Cistanches Herba", CHINESE PHARMACEUTICAL JOURNAL, vol. 46, no. 12, 30 June 2011 (2011-06-30), pages 882 - 887 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4333865A4 (en) * 2021-05-06 2025-01-15 Sinphar Tian-li Pharmaceutical Co., Ltd. (Hangzhou) USE OF AN EXTRACT OF CISTANCHE TUBULOSA IN THE PREPARATION OF A MEDICATION FOR RELIEVING KERATOCONJUNCTIVITIS SCIENCE

Also Published As

Publication number Publication date
CN108420854A (zh) 2018-08-21
MY192107A (en) 2022-07-27
US20180243360A1 (en) 2018-08-30
CN108420854B (zh) 2021-01-19
TWM565575U (zh) 2018-08-21
TWI721248B (zh) 2021-03-11
US10485836B2 (en) 2019-11-26
TW201828955A (zh) 2018-08-16

Similar Documents

Publication Publication Date Title
TWI721248B (zh) 提高耐力表現之抗疲勞組合物
JP6086953B2 (ja) Ａｍｐｋ活性化剤
CN112674351A (zh) 认知功能速度改善用的组合物
CN105285634B (zh) 一种运动训练提效型天然功能饮剂组合物及其应用
JPWO2004112817A1 (ja) セリ科植物由来抽出物およびその製造方法
CN107613998A (zh) 作为有效成分含有阿魏菇水提取物的代谢性疾病的预防和治疗用药物组合物或健康功能性食品
KR101266889B1 (ko) 혈액의 조성 및 기능 회복 효과를 갖는 기능성 식품용 조성물
KR101859166B1 (ko) 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물
CN109380728B (zh) 一种具有辅助降血压功效的组合物及保健食品
KR20180044793A (ko) 항피로 식품 조성물 및 항피로제
TWI676473B (zh) 茯苓皮部萃取物、茯苓新酸ａ、及茯苓新酸ｂ於調節血糖之用途
CN108201544A (zh) 红藜萃取物于调控nos3、plat、f3及／或serpine1基因表现的应用
JPWO2008123417A1 (ja) 抗疲労剤
JP4751066B2 (ja) 治療剤
JP2011032232A (ja) 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP7058407B2 (ja) 経口組成物
US20230218699A1 (en) Composition for enhancing exercise performance and fatigue recovery, containing fermented ripen noni, coconut sugar and muscovado sugar as active ingredients
JP5297867B2 (ja) モロヘイヤ抽出物を含有する抗疲労剤又は体力向上剤
KR102444884B1 (ko) 비타민 b1 및 b2를 고함량으로 함유하는 맥주효모 추출물 및 이의 제조방법
CN110339229B (zh) 一种降黏清血组合物及其应用
KR102240706B1 (ko) 시계꽃 추출물을 함유하는 수면 유도용 조성물
JP2004292355A (ja) 抗ストレス剤
KR20250097672A (ko) 람버티아닉산을 유효성분으로 포함하는 피로개선 또는 운동수행능력 증진용 조성물
KR101468467B1 (ko) 헛개나무 추출물을 함유하는 스트레스 저하용 조성물
CN113100443A (zh) 一种缓解痛风组合物、软胶囊及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18751243

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18751243

Country of ref document: EP

Kind code of ref document: A1